Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11. Mult Scler. 2010. PMID: 20150398 Clinical Trial.
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Clerico M, et al. Among authors: lanzillo r. JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. JAMA Neurol. 2014. PMID: 24977406 Clinical Trial.
Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Moccia M, Lanzillo R, Palladino R, Russo C, Carotenuto A, Massarelli M, Vacca G, Vacchiano V, Nardone A, Triassi M, Morra VB. Moccia M, et al. Among authors: lanzillo r. Clin Chem Lab Med. 2015 Apr;53(5):753-9. doi: 10.1515/cclm-2014-0744. Clin Chem Lab Med. 2015. PMID: 25241733
Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, Postiglione E, De Luca Picione C, Vastola M, Maniscalco GT, Palladino R, Brescia Morra V. Moccia M, et al. Among authors: lanzillo r. J Neurol. 2015;262(4):961-7. doi: 10.1007/s00415-015-7666-y. Epub 2015 Feb 12. J Neurol. 2015. PMID: 25673130
The Framingham cardiovascular risk score in multiple sclerosis.
Moccia M, Lanzillo R, Palladino R, Maniscalco GT, De Rosa A, Russo C, Massarelli M, Carotenuto A, Postiglione E, Caporale O, Triassi M, Brescia Morra V. Moccia M, et al. Among authors: lanzillo r. Eur J Neurol. 2015 Aug;22(8):1176-83. doi: 10.1111/ene.12720. Epub 2015 Apr 27. Eur J Neurol. 2015. PMID: 25912468
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.
Moccia M, Lanzillo R, Palladino R, Chang KC, Costabile T, Russo C, De Rosa A, Carotenuto A, Saccà F, Maniscalco GT, Brescia Morra V. Moccia M, et al. Among authors: lanzillo r. Mult Scler. 2016 Apr;22(5):659-67. doi: 10.1177/1352458515599075. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362896
Quality of life and cognitive functions in early onset multiple sclerosis.
Lanzillo R, Chiodi A, Carotenuto A, Magri V, Napolitano A, Liuzzi R, Costabile T, Rainone N, Freda MF, Valerio P, Brescia Morra V. Lanzillo R, et al. Eur J Paediatr Neurol. 2016 Jan;20(1):158-63. doi: 10.1016/j.ejpn.2015.08.005. Epub 2015 Sep 3. Eur J Paediatr Neurol. 2016. PMID: 26387071
248 results